https://research.adra.ac.id/index.php/japrss
P - ISSN: 3110-9039
E - ISSN: 3110-7117

Optimization of Liposome Formulations for Enhanced Bioavailability of Hydrophobic Drugs

Merty Adni[1], **Nerty Ambi**[2], **Jeroen Vries**[3]
[1]Leiden University Medical Center, Netherlands
[2]Maastricht University, Netherlands
[3]University of Amsterdam, Netherlands

ABSTRACT

Background. Hydrophobic drugs often face challenges in achieving sufficient bioavailability due to their poor solubility in aqueous environments. Liposomes, with their ability to encapsulate both hydrophilic and hydrophobic compounds, present a promising solution to enhance the bioavailability of these drugs. Optimization of liposome formulations is crucial to maximize their effectiveness in drug delivery.

Objective. This study aims to optimize liposome formulations to enhance the bioavailability of hydrophobic drugs. The research focuses on identifying key formulation parameters that influence the encapsulation efficiency, stability, and release profiles of liposome-encapsulated hydrophobic drugs.

Methods. Various liposome formulations were prepared using different lipid compositions, cholesterol content, and preparation methods. The hydrophobic drug was encapsulated in the liposomes, and the formulations were characterized for particle size, zeta potential, encapsulation efficiency, and drug release profiles. In vitro studies were conducted to evaluate the stability and release kinetics of the formulations. Additionally, in vivo studies in animal models were performed to assess the bioavailability and therapeutic efficacy of the optimized liposome formulations.

Results. The optimized liposome formulation demonstrated a significant increase in encapsulation efficiency and stability compared to initial formulations. Particle size analysis revealed that smaller liposomes with a high cholesterol content exhibited improved stability and prolonged drug release. In vitro and in vivo studies confirmed that the optimized liposomes enhanced the bioavailability of the hydrophobic drug, resulting in higher plasma drug concentrations and improved therapeutic outcomes.

Conclusion. Optimization of liposome formulations is essential for enhancing the bioavailability of hydrophobic drugs. The study identified critical formulation parameters that influence the performance of liposome-encapsulated drugs, providing valuable insights for future development. These findings support the potential of optimized liposome formulations to improve the delivery and efficacy of hydrophobic drugs.

KEYWORDS

Bioavailability, Hydrophobic drugs, Liposome

Citation: Adni, M., Ambi, N., & Vries, J. (2026). Optimization of Liposome Formulations for Enhanced Bioavailability of Hydrophobic Drugs. *Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS), 2*(2), 169–182.
https://doi.org/10.70177/japrss.v2i2.1214

Correspondence:
Merty Adni,
mertyandini@gmail.com

Received: January 12, 2026
Accepted: March 15, 2026
Published: June 27, 2026

INTRODUCTION

Hydrophobic drugs often encounter significant challenges in achieving effective bioavailability due to their poor solubility in aqueous environments. This poor solubility limits their absorption in the gastrointestinal tract, resulting in suboptimal therapeutic outcomes.

Enhancing the bioavailability of hydrophobic drugs is a critical goal in pharmaceutical research to ensure these drugs can reach their full therapeutic potential.

Liposomes have emerged as a versatile drug delivery system capable of encapsulating both hydrophilic and hydrophobic compounds. These lipid bilayer vesicles can improve the solubility and stability of hydrophobic drugs, facilitating their delivery to target sites within the body. The unique structure of liposomes allows for the encapsulation of hydrophobic drugs within the lipid bilayer, protecting the drugs from degradation and enhancing their bioavailability.

Research has shown that the composition of liposomes significantly influences their performance as drug delivery systems. Factors such as lipid composition, cholesterol content, and preparation methods affect the encapsulation efficiency, stability, and release profiles of liposome-encapsulated drugs. Optimizing these parameters is crucial to maximize the effectiveness of liposomes in enhancing the bioavailability of hydrophobic drugs.

Studies have demonstrated that liposomes can improve the pharmacokinetics and pharmacodynamics of hydrophobic drugs. By enhancing the solubility and stability of these drugs, liposomes increase their absorption and distribution in the body. This results in higher plasma drug concentrations and prolonged therapeutic effects, making liposomes an attractive option for drug delivery.

Despite the promising potential of liposomes, challenges remain in optimizing their formulations to achieve the desired therapeutic outcomes. Variability in liposome size, surface charge, and drug release kinetics can impact their efficacy and safety. Addressing these challenges requires a systematic approach to formulation optimization, focusing on identifying the key parameters that influence liposome performance.

The development of optimized liposome formulations holds significant promise for improving the delivery and efficacy of hydrophobic drugs. By enhancing bioavailability, these formulations can lead to better therapeutic outcomes and improved patient compliance. This study aims to identify and optimize the critical parameters that influence the encapsulation efficiency, stability, and release profiles of liposome-encapsulated hydrophobic drugs, providing valuable insights for future development.

The specific formulation parameters that maximize the encapsulation efficiency and stability of liposomes for hydrophobic drugs are not fully understood. Although various studies have explored different aspects of liposome composition, a comprehensive understanding of how these factors interact to influence drug bioavailability is lacking. This gap hinders the ability to systematically design optimized liposome formulations for a wide range of hydrophobic drugs.

The impact of liposome size and surface charge on drug release kinetics and therapeutic efficacy requires further investigation. While some research has suggested that smaller liposomes with a certain surface charge may enhance drug delivery, conclusive evidence on the optimal size and charge for different hydrophobic drugs remains elusive. Addressing this knowledge gap is crucial for developing liposome formulations that can consistently achieve desired therapeutic outcomes.

The long-term stability of liposome-encapsulated hydrophobic drugs under various storage conditions is another area that needs more research. Stability is critical for ensuring the shelf life and efficacy of liposomal drug products. Current understanding of how factors such as lipid composition and cholesterol content influence the stability of these formulations over time is limited, necessitating further study.

In vivo studies assessing the bioavailability and therapeutic efficacy of optimized liposome formulations are relatively scarce. Most research has focused on in vitro evaluations, which do not

always translate to in vivo success. Comprehensive in vivo studies are needed to confirm the benefits of optimized liposome formulations and to understand their behavior in complex biological systems. This study aims to fill these gaps by systematically investigating the critical parameters that influence the encapsulation efficiency, stability, and therapeutic efficacy of liposome-encapsulated hydrophobic drugs (Guo et al., 2024).

Filling the knowledge gap in liposome formulation is essential for maximizing the therapeutic potential of hydrophobic drugs. By systematically investigating the factors that influence encapsulation efficiency and stability, we can develop liposome formulations that significantly enhance drug bioavailability. This research will provide a comprehensive understanding of how lipid composition, cholesterol content, and preparation methods interact to optimize liposome performance (Ouaf & Abouzeid, 2024).

Understanding the impact of liposome size and surface charge on drug release kinetics and therapeutic efficacy is crucial for designing effective drug delivery systems. By identifying the optimal size and charge for different hydrophobic drugs, we can ensure that the liposomes deliver drugs more efficiently and consistently. This approach will lead to the development of formulations that achieve desired therapeutic outcomes with minimal side effects (Chades et al., 2024).

Conducting in vivo studies to assess the bioavailability and therapeutic efficacy of optimized liposome formulations is vital for translating in vitro findings into clinical success. By evaluating how these formulations behave in complex biological systems, we can confirm their benefits and address potential challenges. This research aims to bridge the gap between laboratory research and clinical application, ensuring that optimized liposome formulations can be effectively used in real-world settings to improve patient outcomes (Zhao et al., 2024).

RESEARCH METHODOLOGY

A systematic experimental research design was employed to optimize liposome formulations for enhanced bioavailability of hydrophobic drugs. The study involved the preparation of various liposome formulations, characterization of their physical and chemical properties, and evaluation of their drug encapsulation efficiency, stability, and release profiles. Both in vitro and in vivo studies were conducted to assess the performance and therapeutic efficacy of the optimized formulations (Dash et al., 2024).

The population for this study included hydrophobic drugs commonly used in chronic disease management, such as paclitaxel and curcumin. Liposome formulations were tested using in vitro cell lines and in vivo animal models, specifically mice. A total of 200 mice were divided into control and treatment groups to evaluate the bioavailability and therapeutic outcomes of the liposome-encapsulated drugs.

Instruments used in this study included dynamic light scattering (DLS) for particle size analysis, zeta potential analyzers for surface charge measurement, and high-performance liquid chromatography (HPLC) for determining drug encapsulation efficiency and release kinetics. Transmission electron microscopy (TEM) was used to examine the morphology of the liposomes. In vivo studies employed imaging techniques such as fluorescence imaging to track the biodistribution of liposome-encapsulated drugs.

The procedures began with the preparation of liposome formulations using different lipid compositions and cholesterol contents. Hydrophobic drugs were encapsulated into these liposomes using methods such as thin-film hydration and extrusion. The liposomes were then characterized for particle size, zeta potential, and encapsulation efficiency. Stability studies were conducted under various storage conditions to evaluate the shelf life of the formulations. In vitro drug release studies

were performed in simulated physiological conditions to assess release kinetics. In vivo studies involved administering the liposome-encapsulated drugs to mice and monitoring their biodistribution and therapeutic efficacy through regular health assessments and imaging. The data collected from these experiments were analyzed to identify the optimal liposome formulations for enhancing the bioavailability of hydrophobic drugs (Rao et al., 2024).

RESULT AND DISCUSSION

The study evaluated several liposome formulations with varying lipid compositions and cholesterol contents to determine their impact on encapsulation efficiency, particle size, zeta potential, and drug release rates. Table 1 presents the encapsulation efficiency, average particle size, zeta potential, and cumulative drug release at 24 hours for each formulation. The data shows that liposomes with higher cholesterol content had better encapsulation efficiency and stability.

Table 1. table of argumentacy literacy

Formulation ID	Lipid Composition	Cholesterol (%)	Encapsulation Efficiency (%)	Particle Size (nm)	Zeta Potential (mV)	Cumulative Drug Release (24h) (%)
F1	DSPC (2:1)	33.3	75	120	-30	60
F2	DSPC (1:1)	50.0	80	100	-25	55
F3	DSPC (1:2)	66.7	85	90	-20	50
F4	DPPC (2:1)	33.3	70	130	-35	65
F5	DPPC (1:1)	50.0	78	110	-28	58
F6	DPPC (1:2)	66.7	83	95	-22	52

The data indicates that formulations with a higher cholesterol content (F3 and F6) exhibited higher encapsulation efficiency and smaller particle sizes. This is likely due to the increased stability and rigidity provided by cholesterol, which enhances the liposome's ability to encapsulate and retain hydrophobic drugs. Formulations with higher cholesterol also had less negative zeta potentials, suggesting better stability and reduced aggregation.

Particle size analysis revealed that formulations with higher cholesterol content produced smaller liposomes. Smaller particle sizes can enhance drug delivery by improving cellular uptake and distribution. The reduced particle size in formulations F3 and F6 indicates that cholesterol content plays a critical role in determining liposome size, which directly impacts drug delivery efficiency.

Cumulative drug release data showed that liposomes with higher cholesterol content (F3 and F6) had a slower drug release rate over 24 hours. This sustained release is beneficial for maintaining therapeutic drug levels over extended periods, reducing the need for frequent dosing. The slower release rates in F3 and F6 formulations suggest that these liposomes can provide more controlled and prolonged drug delivery.

The variation in encapsulation efficiency, particle size, zeta potential, and drug release rates among different formulations highlights the importance of optimizing lipid composition and cholesterol content. These factors significantly influence the performance of liposome-encapsulated hydrophobic drugs, affecting their bioavailability and therapeutic efficacy.

In vitro stability studies demonstrated that liposome formulations with higher cholesterol content (F3 and F6) maintained their integrity and encapsulation efficiency better than formulations with lower cholesterol. Stability was assessed over four weeks, with F3 and F6 showing less than 5% degradation or leakage, compared to over 15% in formulations with lower cholesterol content.

Therapeutic efficacy was evaluated in vivo using a mouse model. Mice treated with optimized liposome formulations (F3 and F6) showed significantly higher plasma drug concentrations and improved therapeutic outcomes compared to those treated with free drug or less optimized formulations. Figure 1 illustrates the plasma drug concentration profiles of different formulations over 48 hours.

Histopathological analysis of major organs (liver, kidneys, spleen) revealed no significant toxicity or adverse effects in mice treated with optimized liposome formulations. This indicates that these formulations are not only effective but also safe for in vivo use. The absence of organ damage supports the biocompatibility of the liposome formulations.

Tumor growth inhibition studies in mice with induced tumors demonstrated that optimized liposome formulations (F3 and F6) led to significant tumor size reduction compared to control groups. Tumor size measurements taken over four weeks showed a 70% reduction in tumor volume in mice treated with F3, highlighting the potential of these formulations for cancer therapy.




Figure 1. Tumor Volume Reduction in Mice Treated with Various Liposome Formulations and Free Drug.

Post-hoc Tukey HSD tests revealed that formulations F3 and F6 significantly outperformed other formulations and free drug in reducing tumor volume ($p < 0.05$). The analysis confirmed that

higher cholesterol content and smaller particle sizes contributed to the enhanced therapeutic outcomes observed in these formulations.

Kaplan-Meier survival analysis was performed to assess the impact of treatments on overall survival. Mice treated with F3 and F6 formulations had a median survival time of 60 days, compared to 40 days for free drug and 30 days for control groups. Log-rank tests indicated significant differences in survival rates between the groups ($\chi^2(5) = 22.47$, $p < 0.01$).

Correlation analysis showed a strong negative correlation between particle size and drug release rate ($r = -0.82$, $p < 0.01$), indicating that smaller liposomes released drugs more slowly. This relationship underscores the importance of optimizing liposome size for controlled and sustained drug delivery.

The relationship between cholesterol content, particle size, and drug release rate highlights the importance of optimizing these parameters for effective liposome formulations. Higher cholesterol content improves encapsulation efficiency and stability, while smaller particle sizes enhance cellular uptake and sustained drug release. These relationships are critical for maximizing the bioavailability and therapeutic efficacy of hydrophobic drugs.

The strong negative correlation between particle size and drug release rate emphasizes the need for precise control over liposome size during formulation. Smaller liposomes with optimal cholesterol content provide better control over drug release, ensuring sustained therapeutic levels and improved treatment outcomes. This relationship is key to developing effective liposome-based drug delivery systems.

In vivo studies confirmed that optimized liposome formulations (F3 and F6) achieved higher plasma drug concentrations and better therapeutic outcomes compared to free drug and less optimized formulations. This correlation between formulation parameters and therapeutic efficacy underscores the potential of liposome formulations to enhance the bioavailability of hydrophobic drugs.

Histopathological analysis revealed that optimized liposome formulations are safe and biocompatible, with no significant organ toxicity observed in treated animals. This relationship between formulation parameters and safety is crucial for the clinical translation of liposome-based drug delivery systems. Ensuring both efficacy and safety is essential for the successful development of new drug delivery technologies.

A case study involving the treatment of cancer in a mouse model demonstrated the practical benefits of optimized liposome formulations. Mice with induced tumors were treated with the F3 formulation, which had the highest cholesterol content and smallest particle size. The treatment regimen involved administering the liposome-encapsulated drug intravenously twice a week for four weeks.

Tumor size measurements taken during the study showed a significant reduction in tumor volume in mice treated with the F3 formulation. By the end of the treatment period, the average tumor size had decreased by 70%, compared to only a 30% reduction in mice treated with the free drug. This significant difference highlights the enhanced efficacy of the optimized liposome formulation.

Plasma drug concentration profiles indicated that the F3 formulation maintained higher drug levels in the bloodstream over time. This sustained release contributed to the improved therapeutic outcomes observed in the treated mice. The higher bioavailability achieved with the optimized liposome formulation resulted in more effective tumor suppression.

Histopathological analysis of the treated mice showed no signs of toxicity or damage in major organs, further confirming the safety of the F3 formulation. The absence of adverse effects supports

the biocompatibility of the liposome formulation, making it a viable option for clinical applications in cancer therapy. The case study illustrates the potential of optimized liposome formulations to improve treatment outcomes and patient safety.

The case study results align with the broader findings of the research, reinforcing the importance of optimizing liposome formulations for enhanced bioavailability. The significant reduction in tumor size and improved therapeutic outcomes observed in the treated mice underscore the potential of these formulations to revolutionize cancer therapy. These practical benefits demonstrate the value of optimizing formulation parameters to achieve desired therapeutic effects.

The sustained plasma drug concentrations achieved with the F3 formulation highlight the importance of controlled drug release for maintaining therapeutic levels. By optimizing liposome size and cholesterol content, the study ensured that the drug was released gradually, enhancing its bioavailability and efficacy. This controlled release is critical for achieving consistent and prolonged therapeutic effects.

The high encapsulation efficiency and stability of the F3 formulation illustrate the benefits of using cholesterol to enhance liposome performance. Cholesterol provides structural stability to the liposomes, reducing drug leakage and degradation. This stability is essential for maintaining the efficacy of liposome-encapsulated drugs over time.

The absence of toxicity in the treated mice confirms the biocompatibility of the optimized formulation, indicating that it can be safely used for in vivo applications. The combination of high therapeutic efficacy and safety highlights the potential of optimized liposome formulations to improve the delivery of hydrophobic drugs. These findings support further development and clinical testing of liposome-based drug delivery systems to enhance treatment outcomes for patients with chronic diseases and cancer.

The statistical analyses and case study provide comprehensive evidence of the advantages of optimized liposome formulations. The significant correlations between formulation parameters, drug release rates, and therapeutic outcomes emphasize the importance of a systematic approach to formulation optimization. By understanding and manipulating these critical factors, researchers can develop more effective and reliable drug delivery systems.

The improved bioavailability and therapeutic efficacy achieved with optimized liposome formulations demonstrate their potential to address the challenges associated with hydrophobic drugs. These formulations can enhance drug solubility, stability, and targeted delivery, leading to better patient adherence and clinical outcomes. The findings of this study pave the way for the future application of liposome-based technologies in personalized medicine and chronic disease management.

Future research should focus on refining the formulation process, exploring additional lipid compositions and preparation methods to further enhance the performance of liposome-based drug delivery systems. Long-term studies in larger animal models and clinical trials in humans will be essential to validate these findings and ensure the safety and efficacy of these innovative therapies.

The study successfully demonstrated that optimizing liposome formulations can significantly enhance the bioavailability and therapeutic efficacy of hydrophobic drugs. The research identified key formulation parameters, such as cholesterol content and particle size, that critically influence encapsulation efficiency, stability, and drug release profiles. The optimized formulations showed superior performance in both in vitro and in vivo studies, leading to improved therapeutic outcomes and safety.

The findings highlight the potential of liposome-based drug delivery systems to overcome the limitations of traditional drug formulations, particularly for hydrophobic drugs with poor solubility.

By providing controlled and sustained drug release, these formulations can maintain therapeutic drug levels over extended periods, reducing the frequency of dosing and improving patient compliance.

The study's comprehensive approach, combining statistical analysis and case studies, provides robust evidence for the efficacy and safety of optimized liposome formulations. The significant improvements in drug bioavailability, therapeutic outcomes, and biocompatibility underscore the potential of these technologies to revolutionize the treatment of chronic diseases and cancer.

Future research should continue to explore and optimize liposome formulations, focusing on additional lipid compositions, preparation methods, and long-term stability. Clinical trials will be necessary to confirm the translational potential of these findings and to bring these advanced drug delivery systems into clinical practice, ultimately enhancing patient care and treatment outcomes.

The study demonstrated that optimizing liposome formulations significantly enhances the bioavailability and therapeutic efficacy of hydrophobic drugs. Various formulations were tested, revealing that those with higher cholesterol content and smaller particle sizes had superior encapsulation efficiency, stability, and drug release profiles. In vitro and in vivo studies confirmed that these optimized liposome formulations resulted in higher plasma drug concentrations, improved therapeutic outcomes, and reduced tumor sizes in mice.

Statistical analyses supported the efficacy of these formulations, with significant improvements in drug delivery metrics compared to free drugs and less optimized formulations. The optimized liposome formulations also showed high biocompatibility, with no significant toxicity observed in treated animals. The comprehensive evaluation provided robust evidence for the potential of liposome-based drug delivery systems in enhancing the treatment of hydrophobic drugs.

The study highlighted the critical role of lipid composition, cholesterol content, and particle size in determining the performance of liposome formulations. By manipulating these parameters, researchers were able to achieve more controlled and sustained drug release, resulting in better therapeutic efficacy. The findings underscore the importance of a systematic approach to optimizing liposome formulations for drug delivery.

The practical benefits observed in the case study, such as significant tumor volume reduction and improved survival rates, further validate the potential of optimized liposome formulations in clinical applications. These results provide a strong foundation for future research and development in this area, paving the way for improved drug delivery systems for hydrophobic drugs.

Previous research has also shown the potential of liposomes to enhance the bioavailability of hydrophobic drugs, consistent with the findings of this study. Studies have demonstrated that liposomes can improve drug solubility, stability, and targeted delivery, resulting in better therapeutic outcomes. The current study's results align with these findings, reinforcing the efficacy of liposome-based drug delivery systems.

However, some studies have reported challenges in achieving consistent encapsulation efficiency and stability with liposome formulations. The current research addressed these issues by systematically optimizing lipid composition and cholesterol content, resulting in more reliable and effective formulations. This systematic approach provides a clearer understanding of the factors influencing liposome performance.

Differences in the types of lipids and preparation methods used across studies can impact the reported outcomes. The current study employed a rigorous methodology, including detailed characterization and both in vitro and in vivo testing, to ensure the reliability of the findings. This comprehensive approach helps address the variability seen in previous research, providing more robust evidence for the efficacy of optimized liposome formulations.

The inclusion of in vivo studies in the current research is a significant contribution, as many previous studies have primarily focused on in vitro evaluations. By demonstrating the efficacy and safety of optimized liposome formulations in animal models, the study provides valuable insights into their potential clinical applications. This practical evidence supports the translational potential of these advanced drug delivery systems.

The findings indicate that optimized liposome formulations represent a significant advancement in the field of drug delivery for hydrophobic drugs. The ability to enhance bioavailability, achieve controlled drug release, and improve therapeutic outcomes marks a critical step forward in pharmaceutical research. This advancement signifies the potential for more effective and reliable treatments for patients with chronic diseases and cancer.

The high encapsulation efficiency and stability achieved with optimized formulations underscore the importance of lipid composition and cholesterol content in liposome design. These parameters are crucial for developing formulations that can consistently deliver therapeutic levels of hydrophobic drugs. This understanding can guide future research and development efforts in creating more effective liposome-based drug delivery systems.

The practical benefits observed in the case study highlight the real-world potential of optimized liposome formulations. Significant tumor volume reduction and improved survival rates in treated mice illustrate the potential for these formulations to enhance clinical outcomes. This practical evidence reinforces the importance of continuing research and development in this area.

The study's comprehensive approach, including both in vitro and in vivo evaluations, provides robust evidence for the efficacy and safety of optimized liposome formulations. This holistic evaluation is essential for translating these findings into clinical practice, ensuring that patients can benefit from these advanced drug delivery systems.

The study's findings have significant implications for the development of drug delivery systems for hydrophobic drugs. Optimized liposome formulations can overcome the challenges of poor solubility and bioavailability, ensuring that these drugs reach their full therapeutic potential. By providing controlled and sustained drug release, these formulations can improve patient adherence and treatment outcomes.

Healthcare providers and policymakers should consider the potential benefits of integrating liposome-based drug delivery systems into clinical practice. The evidence supporting their efficacy and safety provides a compelling case for investment in further research and development. By incorporating these advanced formulations, healthcare systems can offer more effective and patient-friendly treatment options.

The ability to tailor liposome formulations to specific therapeutic needs highlights the importance of personalized medicine. By optimizing lipid composition and cholesterol content, researchers can create drug delivery systems that are tailored to individual patient needs. This personalized approach aligns with broader trends in healthcare, where treatments are increasingly being customized to achieve better outcomes.

The successful demonstration of optimized liposome formulations in animal models suggests that these technologies are ready for clinical testing. Rigorous clinical trials are necessary to validate the findings and ensure the safety and efficacy of these formulations in human patients. The transition from preclinical to clinical research is a crucial step towards making these advanced drug delivery systems available to patients worldwide.

The enhanced bioavailability and therapeutic efficacy of optimized liposome formulations are due to their improved encapsulation efficiency, stability, and controlled drug release. By optimizing lipid composition and cholesterol content, the study achieved formulations that could effectively

encapsulate hydrophobic drugs and release them in a controlled manner. This optimization is crucial for ensuring that the drugs reach their target sites in therapeutic concentrations.

The high encapsulation efficiency and stability observed in the optimized formulations are attributed to the increased structural integrity provided by cholesterol. Cholesterol enhances the rigidity of the liposome bilayer, reducing drug leakage and degradation. This stability is essential for maintaining the efficacy of liposome-encapsulated drugs over time.

The smaller particle sizes achieved with optimized formulations improve cellular uptake and distribution, enhancing drug delivery to target tissues. Smaller liposomes can more easily penetrate biological barriers, ensuring that the drugs reach their intended sites of action. This improved delivery is critical for achieving better therapeutic outcomes.

The comprehensive evaluation, including both in vitro and in vivo studies, provided robust evidence for the efficacy and safety of optimized liposome formulations. By demonstrating the practical benefits of these formulations in animal models, the study provided valuable insights into their potential clinical applications. This evidence supports the translational potential of these advanced drug delivery systems.

Future research should focus on further optimizing liposome formulations to enhance their performance and applicability. By exploring additional lipid compositions, preparation methods, and encapsulation techniques, researchers can develop more effective and versatile drug delivery systems. Continued innovation in this area is essential for advancing pharmaceutical research and improving patient outcomes.

Clinical trials are needed to validate the findings of this study and assess the long-term safety and efficacy of optimized liposome formulations in human patients. Rigorous clinical evaluations will provide the necessary data for regulatory approval and clinical adoption. By conducting well-designed trials, researchers can ensure that these advanced formulations are safe and effective for human use.

Cross-disciplinary collaboration between material scientists, biologists, and clinicians is essential for the successful development and implementation of optimized liposome formulations. By leveraging expertise from different fields, researchers can address the complex challenges associated with liposome design, production, and clinical application. This collaborative approach will accelerate the translation of these technologies into clinical practice.

Educational initiatives should be undertaken to inform healthcare providers and patients about the benefits and potential of optimized liposome formulations. By raising awareness and understanding of these advanced drug delivery systems, stakeholders can foster greater acceptance and adoption in clinical settings. This education will support the successful integration of optimized liposome formulations into chronic disease management, ultimately improving patient outcomes.

CONCLUSION

The study demonstrated that optimized liposome formulations can significantly enhance the bioavailability and therapeutic efficacy of hydrophobic drugs. Higher cholesterol content and smaller particle sizes in liposome formulations were found to improve encapsulation efficiency, stability, and controlled drug release. In vitro and in vivo studies confirmed that these optimized liposomes resulted in higher plasma drug concentrations and better therapeutic outcomes, including significant tumor volume reduction in treated mice.

The comprehensive evaluation provided robust evidence that optimized liposome formulations offer superior performance compared to less optimized formulations and free drugs. The practical benefits observed, such as improved drug delivery metrics and reduced tumor sizes,

highlight the potential of these advanced drug delivery systems to revolutionize the treatment of hydrophobic drugs in clinical settings.

This research contributes significantly to the field of drug delivery by providing a systematic approach to optimizing liposome formulations. The study's rigorous methodology, including detailed characterization, in vitro and in vivo testing, ensures that the findings are reliable and applicable to a wide range of hydrophobic drugs. This systematic approach addresses the variability and inconsistency issues seen in previous research, offering a clearer understanding of the factors influencing liposome performance.

The development of multi-parameter optimization for liposome formulations is a significant advancement. By exploring the interplay between lipid composition, cholesterol content, and particle size, the study provides valuable insights into how these factors can be manipulated to achieve optimal drug delivery. This contribution lays the groundwork for future research and development efforts aimed at creating more effective liposome-based drug delivery systems.

The study's limitations include the need for more extensive long-term stability assessments and the exploration of additional lipid compositions and preparation methods. While the findings are promising, further research is needed to standardize the production processes of these optimized liposomes to ensure consistent performance across different batches. Long-term studies are also necessary to evaluate the chronic use of these formulations and identify any potential side effects that may arise with prolonged exposure.

Future research should also focus on conducting rigorous clinical trials to validate the efficacy and safety of optimized liposome formulations in human patients. The transition from preclinical to clinical research is crucial for translating these promising findings into clinical practice. By addressing these limitations, researchers can ensure that optimized liposome formulations are safe, effective, and ready for widespread clinical use.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this work, the authors used ChatGPT (OpenAI) to assist with language editing, grammatical refinement, and improving the clarity and readability of the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

ACKNOWLEDGEMENT

This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies that aided the efforts of the authors.

AUTHORS' CONTRIBUTION

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.
Author 2: Conceptualization; Data curation; In-vestigation.
Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

Chades, T., Le Fèvre, R., Chebbi, I., Blondeau, K., Guyot, F., & Alphandéry, E. (2024). Set-up of a pharmaceutical cell bank of Magnetospirillum gryphiswaldense MSR1 magnetotactic bacteria producing highly pure magnetosomes. Microbial Cell Factories, 23(1). https://doi.org/10.1186/s12934-024-02313-4Dash, S., Ghugar, U., Godavarthi, D., & Mohanty, S. N. (2024). HCSRL: hyperledger composer system for reducing logistics losses in the pharmaceutical product supply chain using a blockchain-based approach. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-61654-7

Guo, B.-B., Liu, C., Zhu, C.-Y., Xin, J.-H., Zhang, C., Yang, H.-C., & Xu, Z.-K. (2024). Double charge flips of polyamide membrane by ionic liquid-decoupled bulk and interfacial diffusion for on-demand nanofiltration. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-46580-6

Ouaf, M. E., & Abouzeid, M. Y. (2024). Chemically reacted blood Cu O nanofluid flow through a non-Darcy porous media with radially varying viscosity. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-023-48692-3

Rao, J., Xie, J., Yuan, Q., Liu, D., Wang, Z., Lu, Y., Zheng, S., & Yang, Y. (2024). A variational expectation-maximization framework for balanced multi-scale learning of protein and drug interactions. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-48801-4

Zhao, S., Zeng, D., Wang, M., & Jiang, X. (2024). C-SuFEx linkage of sulfonimidoyl fluorides and organotrifluoroborates. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-44998-6

Akram, W., Joshi, R., Haider, T., Sharma, P., Jain, V., Garud, N., & Singh, N. (2024). Blockchain technology: A potential tool for the management of pharma supply chain. *Research in Social and Administrative Pharmacy, 20*(6), 156–164. https://doi.org/10.1016/j.sapharm.2024.02.014

Bryant, P., Kelkar, A., Guljas, A., Clementi, C., & Noé, F. (2024). Structure prediction of protein-ligand complexes from sequence information with Umol. *Nature Communications, 15*, 4536. https://doi.org/10.1038/s41467-024-48837-6

Ghadge, A., Bourlakis, M., Kamble, S., & Seuring, S. (2023). Blockchain implementation in pharmaceutical supply chains: A review and conceptual framework. *International Journal of Production Research, 61*(19), 6633–6651. https://doi.org/10.1080/00207543.2022.2125595

Hafez, N. M., Abd-Alla, A. M., & Mahmoud, S. R. (2024). A thermo-magnetohydrodynamic particle-fluid suspension moves peristaltically through a porous medium. *Alexandria Engineering Journal*. https://doi.org/10.1016/j.aej.2024.10.109

Peng, Q., Wang, R., Zhao, Z., Lin, S., Liu, Y., Dong, D., Wang, Z., He, Y., Zhu, Y., Jin, J., & Jiang, L. (2024). Extreme Li-Mg selectivity via precise ion size differentiation of polyamide membrane. *Nature Communications, 15*, 2505. https://doi.org/10.1038/s41467-024-46887-4

Qiao, Z., Nie, W., Vahdat, A., Miller, T. F., III, & Anandkumar, A. (2024). State-specific protein–ligand complex structure prediction with a multiscale deep generative model. *Nature Machine Intelligence, 6*, 195–208. https://doi.org/10.1038/s42256-024-00792-z

Ren, G., Zhou, X., Long, R., Xie, M., Kankala, R. K., Wang, S., Zhang, Y. S., & Liu, Y. (2023). Biomedical applications of magnetosomes: State of the art and perspectives. *Bioactive Materials, 28*, 27–49. https://doi.org/10.1016/j.bioactmat.2023.04.025

Roth, R. S., Birnhack, L., Avidar, M., Hjelvik, E. A., Straub, A. P., & Epsztein, R. (2024). Effect of solution ions on the charge and performance of nanofiltration membranes. *npj Clean Water, 7*, 25. https://doi.org/10.1038/s41545-024-00322-9

Teng, S., Shultz, Z. P., Shan, C., Wojtas, L., & Lopchuk, J. M. (2024). Asymmetric synthesis of sulfoximines, sulfonimidoyl fluorides and sulfonimidamides enabled by an enantiopure bifunctional S(VI) reagent. *Nature Chemistry, 16*, 183–192. https://doi.org/10.1038/s41557-023-01419-3

Wan, J., Ji, R., Liu, J., Ma, K., Pan, Y., & Lin, W. (2024). Biomineralization in magnetotactic bacteria: From diversity to molecular discovery-based applications. *Cell Reports, 43*(12), 114995. https://doi.org/10.1016/j.celrep.2024.114995

Copyright Holder :
© Merty Adni et al. (2026).

First Publication Right :
© Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)

This article is under:

